Analysis of clinical characteristics of immune-related adverse events caused by perioperative immunotherapy for esophageal cancer
Objective To analyze the clinical characteristics of immune-related adverse events(irAEs)causde by periop-erative immunotherapy for esophageal cancer,and provide reference for irAEs management.Methods The medical records of esophageal cancer patients receiving PD-1 inhibitors during the perioperative period in the first medical center of Chinese PLA General Hospital from March 2020 to August 2022 were collected.Clinical characteristics,intervention and outcome of irAEs were analyzed,and the management of irAEs caused by perioperative immunotherapy were discussed.Results A total of 66 patients were included.Nine patients(28.79%)experienced irAEs.IrAEs occurred 24 times,involving multiple systems.Most of the cases were mild or moderate,and symptoms could be improved after symptomatic treatment or glucocorticoid in-tervention.The incidence of irAEs in patients aged≤60 years was significantly increased.Three patients delayed operation or stopped immunotherapy due to irAEs.Conclusions The perioperative application of PD-1 inhibitors in esophageal cancer pa-tients had good safety.Clinical management should be strengthened to ensure the safety of perioperative immunotherapy and fully promote the improvement of clinical outcomes.
perioperative period of esophageal cancerimmune-related adverse eventsprogrammed death-1 inhibitormanagement recommendations for adverse events
NETL
NSTL
万方数据
